Latest research on Atomoxetine

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Latest findings

We were unable to identify any studies addressing treatment with Atomoxetine for ADHD in adults aged ≥50 years, but one relevant paper presented data from a post hoc analysis using data from two double-blind, placebo-controlled clinical trials of Atomoxetine in adult ADHD. [source, 2016]
The Atomoxetine study by Durell et al79 showing lower effect sizes in the middle-aged group (mean age 43.4 years) than in the younger adults may point in the same direction, suggesting that age may be a predictor of reduced efficacy of pharmacological treatment in adult ADHD. [source, 2016]
Three children were changed from dexamphetamine to Methylphenidate and four children were trialled on Atomoxetine. [source, 2016]
In separate experiments, the D1 Dopamine receptor antagonist SCH-23390 was administered five minutes before Dextroamphetamine or Atomoxetine. [source, 2015]
Time to righting was compared among the saline, Dextroamphetamine, and Atomoxetine groups using 95% confidence intervals. [source, 2015]
A Bayesian Monte Carlo procedure was used to compute 95% credible intervals to assess the effects of Dextroamphetamine and Atomoxetine on return of righting during continuous Sevoflurane general anesthesia, as described previously [13, 17, 20]. [source, 2015]
Five minutes later, Atomoxetine or Dextroamphetamine was administered. [source, 2015]
The final mean inhaled concentration of Sevoflurane was 1.7% (95% CI: 1.6 to 1.7%) for both the Atomoxetine and Dextroamphetamine groups. [source, 2015]
However, under the same experimental conditions Atomoxetine did not restore righting in any animals (n = 6) during continuous Sevoflurane general anesthesia, even at the highest dose of 3 mg/kg (Fig 1C). [source, 2015]
Similar to normal saline, arousal behaviors were not observed after the administration of Atomoxetine during Sevoflurane anesthesia. [source, 2015]